Free Trial

Fulcrum Therapeutics (FULC) Earnings Date, Estimates & Call Transcripts

Fulcrum Therapeutics logo
$6.49 -0.32 (-4.70%)
Closing price 04:00 PM Eastern
Extended Trading
$6.49 0.00 (0.00%)
As of 07:32 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Fulcrum Therapeutics Earnings Summary

Fulcrum Therapeutics posted Q2 2025 earnings on July 29, 2025, reporting an EPS of -$0.28, which topped the consensus estimate of -$0.29 by $0.01. With a trailing EPS of -$1.22, Fulcrum Therapeutics' earnings are expected to decrease next year, from ($0.16) to ($1.08) per share.

Latest Q2
Earnings Date
Jul. 29Estimated
Consensus EPS
(Jul. 29)
-$0.29
Actual EPS
(Jul. 29)
-$0.28 Beat By $0.01

Q2 2025 Earnings Resources

Get Fulcrum Therapeutics Earnings Alerts

Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Fulcrum Therapeutics and other key companies, straight to your inbox.

Sign Up
Skip Charts & View Estimated and Actual Earnings Data

FULC Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

FULC Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

Fulcrum Therapeutics Analyst EPS Estimates

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20252-$0.35-$0.27-$0.31
Q2 20252-$0.34-$0.28-$0.31
Q3 20252-$0.34-$0.26-$0.30
Q4 20252-$0.34-$0.28-$0.31
FY 2025 8 -$1.37 -$1.09 -$1.23
Q1 20261-$0.34-$0.34-$0.34
Q2 20261-$0.33-$0.33-$0.33
Q3 20261-$0.33-$0.33-$0.33
Q4 20261-$0.33-$0.33-$0.33

Fulcrum Therapeutics Earnings History by Quarter

DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails
7/29/2025Q2 2025-$0.29-$0.28+$0.01-$0.28--
5/1/2025Q1 2025-$0.29-$0.28+$0.01-$0.28--
2/25/2025Q4 2024-$0.28-$0.31 -$0.03-$0.31--
7/31/2024Q2 2024-$0.06$0.87+$0.93$0.87$80.00M$80.00M
5/13/2024Q1 2024-$0.44-$0.43+$0.01-$0.43--
2/27/2024Q4 2023-$0.44-$0.40+$0.04-$0.40$0.65M$0.87M
11/7/2023Q3 2023-$0.44-$0.39+$0.05-$0.39$1.81M$0.76M

Fulcrum Therapeutics Earnings - Frequently Asked Questions

Fulcrum Therapeutics (NASDAQ:FULC) last announced its quarterly earning data on Tuesday, July 29, 2025. Learn more on FULC's earnings history.

In the previous quarter, Fulcrum Therapeutics (NASDAQ:FULC) reported ($0.28) earnings per share (EPS) to beat the analysts' consensus estimate of ($0.29) by $0.01. Learn more on analysts' earnings estimate vs. FULC's actual earnings.

Fulcrum Therapeutics (NASDAQ:FULC) has a recorded annual revenue of $80 million.

Fulcrum Therapeutics (NASDAQ:FULC) has a recorded net income of -$9.73 million. FULC has generated -$1.22 earnings per share over the last four quarters.

Fulcrum Therapeutics' earnings are expected to decrease from ($0.16) per share to ($1.08) per share in the next year.

More Earnings Resources from MarketBeat



This page (NASDAQ:FULC) was last updated on 8/8/2025 by MarketBeat.com Staff
From Our Partners